Contextualizing Golcadomide's Efficacy Signal in the RRFL Landscape

This episode, titled 'Contextualizing Golcadomide's Efficacy Signal in the RRFL Landscape,' features Christina Poh, MD discussing the following critical questions:

Golcadomide represents a first-in-class oral CELMoD agent. With a 97% ORR and 78% CRR at the 0.4 mg dose, and responses appearing durable with 91% of CR patients remaining in remission at data cutoff, how do you contextualize this efficacy signal in the broader RRFL treatment landscape, acknowledging this is still an early phase study?

Given the access and geographic barriers we discussed earlier in this conversation, how significant is the convenience factor of an oral agent in your thinking about treatment selection for RRFL?

Christina Poh described the early phase efficacy data for golcadomide as highly impressive, noting that the high overall response rates and durability of responses a very promising signal that she expects will translate into a meaningful role for this first-in-class oral CELMoD agent in the relapsed or refractory follicular lymphoma treatment landscape in the near future. She also highlighted the significant clinical and practical value of golcadomide's oral administration route, framing it within the broader concept of time toxicity and noting that an effective oral option that reduces this burden would be highly appealing to patients and could meaningfully improve quality of life for those managing a chronic, relapsing disease.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

In the next episode, 'Beyond the Trial: Real-World Evidence for Bispecific Antibodies Across a Broad RRFL Population,' Christina Poh will continue her discussion on follicular lymphoma and highlight real-world data from eight CUBIC centers on mosunetuzumab and epcoritamab and how findings around baseline disease characteristics and prior treatment history inform patient selection for bispecific antibody therapy.